Successful Management of a ROS1-Rearranged Pulmonary Pleomorphic Carcinoma Using Serial Tyrosine Kinase Inhibitors

Pulmonary pleomorphic carcinoma (PPC) generally lacks actionable driver mutations such as epidermal growth factor receptor mutations or anaplastic lymphoma kinase or c-ros oncogene 1 (ROS1) rearrangements. The response to crizotinib, ceritinib, brigatinib, and lorlatinib in ROS1-positive advanced no...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chang-Wei, Yang, Ching-Yao, Chang, Yih-Leong, Shih, Jin-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553601/
https://www.ncbi.nlm.nih.gov/pubmed/33116594
http://dx.doi.org/10.2147/OTT.S262653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553601/
https://www.ncbi.nlm.nih.gov/pubmed/33116594
http://dx.doi.org/10.2147/OTT.S262653

Ejemplares similares